References
- Rinke T. PBMs just say no to some drugs – but not to others. Manag Care 2015;24:24-5
- Calandra R. PBMs: new power and influence. Manag Care 2015;24:22-3,26
- Fein A. Here come the 2016 PBM formulary exclusion lists! Drug Channels. 2015. Available at: http://www.drugchannels.net/2015/08/here-come-2016-pbm-formulary-exclusion.html [Last accessed 12 May 2017]
- Nguyen E, Weeda ER, Sobieraj DM, et al. Impact of non-medical switching on clinical and economic outcomes, resource utilization and medication-taking behavior: a systematic literature review. Curr Med Res Opin 2016;32:1281-90
- Johnston A, Stafylas P, Stergiou GS. Effectiveness, safety and cost of drug substitution in hypertension. Br J Clin Pharmacol 2010;70:320-34
- Happe LE, Clark D, Holliday E, et al. A systematic literature review assessing the directional impact of managed care formulary restrictions on medication adherence, clinical outcomes, economic outcomes, and health care resource utilization. J Manag Care Spec Pharm 2014;20:677-84
- Non-medical switching bills announced in three more states. US Pain Foundation. 2017. Available at: https://www.uspainfoundation.org/news/non-medical-switchinging-bills-announced-three-states/ [Last accessed 12 May 2017]
- Update on nonmedical switching efforts. US Pain Foundation. 2017. Available at: https://www.uspainfoundation.org/news/update-nonmedical-switchinging-efforts/ [Last accessed 8 May 2017]
- Ollove M. New rules aim to keep patients on medications that work. The Pew Charitable Trusts. 2017. Available at: http://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2017/02/02/new-rules-aim-to-keep-patients-on-medications-that-work [Last accessed 14 July 2017]
- Menke A, Casagrande S, Geiss, et al. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA 2015;314:1021-9
- Grandy S, Fox KM, the SHIELD Study Group. Change in health status (EQ-5D) over 5 years among individuals with and without type 2 diabetes mellitus in the SHIELD longitudinal study. Health Qual Life Outcomes 2012;10:99
- Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013;24:302-8
- Zhuo X, Zhang P, Hoerger TJ. Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med 2013;45:253-61
- Kodjak A. Will your prescription meds be covered next year? Better check! Morning Edition, National Public Radio. 2016. Available at: http://www.npr.org/sections/health-shots/2016/08/15/489790412/will-your-prescription-meds-be-covered-next-year-better-check [Last accessed 12 May 2017]
- Bryant GA, McDanel DL, Horner KE, et al. Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir. Pharmacotherapy 2013;33:56-62
- Asias BD, Stock EM, Small NL, et al. Clinical and financial outcomes of switchinging insulin glargine to insulin detemir in a veteran population with type 2 diabetes. J Diabetes Metab Disord 2015;14:53
- Comprehensive diabetes care: the HEDIS measure. The National Committee for Quality Assurance. Available at: http://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality/2016-table-of-contents/diabetes-care [Last accessed 14 July 2017]
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9
- Manley HJ, McClaran ML, Overbay DK, et al. Factors associated with medication-related problems in ambulatory hemodialysis patients. J Kidney Dis 2003;41:386-93
- Westerlund T, Gelin U, Pettersson E, et al. A retrospective analysis of drug-related problems documented in a national database. Int J Clin Pharm 2013;35:202-9
- Bjornsdottir US, Gizurarson S, Sabale U. Potential negative consequences of non-consented switch of inhaled medications and devices in asthma patients. Int J Clin Pract 2013;67:904-10
- Mustafa FA. Switching away from pipotizine palmitate: a naturalistic study. Ther Adv Psychopharmacol 2017;7:25-8
- Gibofsky A, Skup M, Johnson S, et al. Analysis of outcomes after non-medical switching of anti-tumor necrosis factor agents. Ann Rheum Dis 2015;74:701
- Lebwohl M, Skup M, Yang H, et al. Clinical outcomes associated with switching or discontinuation of anti-TNF inhibitors for non-medical reasons. Ann Rheum Dis 2015;74:465
- Wolf D, Skup M, Yang H, et al. Clinical outcomes associated with switching or discontinuation from anti-TNF inhibitors for nonmedical reasons. Clin Ther 2017;39:849-62.e6
- American Diabetes Association deeply concerned with recent prescription drug formulary trends. American Diabetes Association. 2017. Available at: http://www.diabetes.org/newsroom/press-rele-ases/2017/american-diabetes-association-deeply-concerned-with-recent-prescription-drug-formulary-trends.html [Last accessed 21 August 2017]
- CS/HB 95: consumer protection from nonmedical changes to prescription drug formularies. Florida State Senate. 2016. Available at: http://www.flsenate.gov/Session/Bill/2017/00095/?Tab=BillText [Last accessed 6 May 2017]
- H.B. No. 2882. Texas State Legislature. 2017. Available at: http://www.capitol.state.tx.us/tlodocs/85R/billtext/html/HB02882I.htm [Last accessed 7 May 2017]
- Senate, No. 2969: state of New Jersey, 217th legislature. New Jersey State Senate. 2017. Available at: http://www.njleg.state.nj.us/2016/Bills/S3000/2969_I1.HTM [Last accessed 6 May 2017]
- SB 5160-2017-18: concerning prescription drug insurance continuity of care. Washington State Legislature. 2017. Available at: http://app.leg.wa.gov/billsummary?BillNumber=5160&Year=2017 [Last accessed 6 May 2017]
- Assembly Bill A2317. New York State Assembly. 2017. Available at: https://www.nysenate.gov/legislation/bills/2017/A2317 [Last accessed 6 May 2017]